托法替布减量维持斑秃治疗缓解的单中心回顾性研究
本研究纳入46例经托法替布治疗达到完全毛发再生的斑秃患者,在48周随访期内评估以患者为中心的个体化减量方案。结果显示第24周和第48周的疾病控制率分别为95.7%和93.5%,80.4%的患者成功减量,累计药物暴露减少1198 mg,且疗效丧失罕见。
要点
- 托法替布减量策略在斑秃完全缓解患者中可行,48周内疾病控制率维持93.5%以上。
- 80.4%的患者成功实现剂量降低,累计药物暴露减少1198 mg。
- 减量后疗效丧失(SALT≥20)罕见,第48周仅2.2%。
核心结论
- 以患者为中心的托法替布减量策略对治疗有效的斑秃患者可行,可在不损害疗效的前提下减少治疗负担。
研究设计与样本
- 单中心回顾性观察性队列研究,纳入46例经托法替布治疗达到完全毛发再生并接受结构化减量的斑秃患者,随访48周。
主要发现
- 第24周疾病控制(SALT≤10)率为95.7%(44/46),第48周为93.5%(43/46)。
- 疗效丧失(SALT≥20)第24周为0.0%(0/46),第48周为2.2%(1/46)。
- 80.4%(37/46)的患者成功实现剂量降低。
- 至第48周,个体化减量策略使累计药物暴露减少1198 mg,从3360 mg降至2162 mg。
- 未发现减量成功的显著预测因素。
临床怎么用
- 对托法替布治疗达到完全缓解的斑秃患者,可考虑个体化减量以降低药物暴露和治疗负担。
- 减量期间需定期评估SALT评分以监测疾病控制情况。
局限性
- 样本量小,随访时间相对较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The advent of Janus kinase inhibitors has revolutionized the management of alopecia areata (AA). However, evidence remains scarce regarding the maintenance of disease control following an individual-based taper strategy. OBJECTIVE: To assess the outcome of a patient-centered tofacitinib dosing regimen in patients with AA who were in complete remission. METHODS: This retrospective observational cohort study included 46 patients with AA who achieved complete hair regrowth on tofacitinib and underwent structured dose tapering between February 2021 and July 2025. Clinical outcomes, cumulative drug exposure, and adverse events were assessed over a 48-week follow-up period. RESULTS: Disease control (Severity of Alopecia Tool ≤10) was consistently maintained, with rates of 95.7% (44/46) at week 24 and 93.5% (43/46) at week 48, while loss of treatment benefit (Severity of Alopecia Tool ≥20) remained rare, occurring in 0.0% (0/46) at week 24 and 2.2% (1/46) at week 48. A successful dose reduction was achieved in 80.4% (37/46) of patients. By week 48, the individualized tapering strategy resulted in a cumulative reduction of 1198 mg in drug exposure, decreasing from 3360 mg to 2162 mg. No significant predictors of tapering success were identified. LIMITATIONS: Small sample size, relatively short duration of follow-up. CONCLUSION: A patient-centered tofacitinib tapering strategy is feasible for responders and may reduce treatment burden without compromising efficacy.
引用
- Huang J, Jian J, Li M, et al. Sustaining treatment response in alopecia areata through tofacitinib dose tapering: A single-center retrospective study. J Am Acad Dermatol. 2025. PMID: 41371419. doi:10.1016/j.jaad.2025.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。